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Background: The origins of neointimal smooth muscle cells that arise following vascular injury remains
controversial. Studies have suggested that these cells may arise from previously differentiated medial vascular
smooth muscle cells, resident stem cells or blood born progenitors. In the current study we examined the
contribution of the previously differentiated vascular smooth muscle cells to the neointima that forms following
carotid artery ligation.
Methods: We utilized transgenic mice harboring a cre recombinase-dependent reporter gene (mTmG). These mice
express membrane targeted tandem dimer Tomato (mTomato) prior to cre-mediated excision and membrane
targeted EGFP (mEGFP) following excision. The mTmG mice were crossed with transgenic mice expressing either
smooth muscle myosin heavy chain (Myh11) or smooth muscle α-actin (Acta2) driven tamoxifen regulated cre
recombinase. Following treatment of adult mice with tamoxifen these mice express mEGFP exclusively in
differentiated smooth muscle cells. Subsequently vascular injury was induced in the mice by carotid artery
ligation and the contribution of mEGFP positive cells to the neointima determined.
Results: Analysis of the cellular composition of the neointima that forms following injury revealed that mEGFP
positive cells derived from either Mhy11 or Acta2 tagged medial vascular smooth muscle cells contribute to the
majority of neointima formation (79 ± 17% and 81 ± 12%, respectively).
Conclusion: These data demonstrate that the majority of the neointima that forms following carotid ligation is
derived from previously differentiated medial vascular smooth muscle cells.
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Vascular smooth muscle cells (VSMCs) are the major
contractile components of the vascular system. They are
critically important for regulating blood pressure and
flow throughout the vascular system. Unlike skeletal and
cardiac muscle cells, VSMCs are remarkably plastic and
modulate their phenotype in response to extracellular
cues during the development and progression of a var-
iety of diseases including atherosclerosis, hypertension,
stenosis following injury and restenosis following vascu-
lar interventions. Cardiovascular disease is the leading* Correspondence: pherring@iupui.edu
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unless otherwise stated.cause of death among the US population, yet despite in-
tense research efforts a number of basic questions regard-
ing the etiology of cardiovascular disease remain elusive.
Classically these diseases are described as being associated
with dedifferentiated VSMCs that have decreased expres-
sion of proteins required for the normal contractile func-
tion, increased expression of extracellular matrix proteins
and increased cell proliferation [1]. These proliferating
dedifferentiated VSMCs are a major component of neoin-
timal lesions and atherosclerotic plaques. Neointimal
VSMCs have been proposed to arise from several sources,
including blood and bone marrow derived precursor cells,
dedifferentiated medial VSMCs, resident progenitor cells
and adventitial fibroblasts. However, recent definitive
studies showed a relatively minor contribution of bloodLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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erosclerotic plaque VSMC population [2-5]. The most
widely accepted paradigm that neointimal VSMCs arise
from the dedifferentiation and migration of medial
VSMCs has been recently challenged [6]. This finding
has stimulated much controversy in the field [7] and has
prompted us to further investigate the origin of these
cells. Using a genetic fate mapping approach with tam-
oxifen regulated smooth muscle-specific cre recombinase
and a dual color cre-dependent reporter gene we un-
equivocally show that the neointimal SMCs that arise
following carotid artery ligation are largely derived
from the previously differentiated medial VSMCs.
Methods
Transgenic mice and carotid ligation
All animal procedures were performed using procedures
approved by the Indiana University School of Medicine
Institutional Animal Care and Use committee under proto-
col number 10310. Smooth muscle myosin heavy chain
(Myh11) creER(T2)-/+ mice [8] (on a C57BL6 background)
and smooth muscle α-actin (Acta2) creER(T2)-/+ mice
[9] were crossed with mTmG reporter mice (Jackson strain:
B6.129(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J)
(Figure 1). creER(T2) transgenes were used under agree-
ment from the Institut de Génétique et de Biologie Molécu-
laire et Cellulaire (IGBMC). Double heterozygous transgenic+ Tam
nuclear
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Figure 1 Schematic representation of the mTmG reporter strain. Th
26Sortm4(ACTB-tdTomato,-EGFP)Luo/J ) contain a single copy of the transgene
comprised of a chimeric CMV, β-actin promoter driving the expression o
cre-mediated excision the mTomato transgene is removed such that the
The reporter mice were crossed with transgenic mice that express a tam
by either the Myh11 promoter or the Acta2 promoter. Double heterozygmice were used for all experiments unless indicated other-
wise. At 5-6 weeks of age mice were treated with Tam-
oxifen (1 mg/mouse IP) or corn oil control, once a day
for 5 days. 2 weeks following the last treatment the left
carotid artery was ligated as described previously [10].
Prior to surgery mice were anesthetized with intraperi-
toneal injection of ketamine/xylazine (0.088 mg/gm,
0.012 mg/gm). Following surgery mice were given a single
subcutaneous injection of carprofen analgesic (0.5 mg).
At various times following ligation mice were sacrificed
under anesthesia (intraperitoneal injection of ketamine/
xylazine (0.088 mg/gm, 0.012 mg/gm) and the injured
and control contralateral carotid arteries were harvested
and fixed in 4% paraformaldehyde for 2 hours on ice.
Following fixation, vessels were washed in phosphate
buffered saline for 3× 5 minutes and then frozen in
OCT tissue freezing media (Tissue-Tech) on a bed of
dry ice/2-methylbutane. 8 μm cryosections were cut and
stored at -80°.
Histological and immuno-staining
OCT was removed from sections by 3, 5 minute washes
in Tris buffered saline (TBS; 100 mM Tris pH7.6,
150 mM NaCl). Slides were mounted in Prolong Gold
containing DAPI (Invitrogen) and visualized by confocal
microscopy (Olympus Fluoview FV1000). For immuno-
fluorescent staining cryosections were permeabilized inCorn oil
cytoplasmic
oxifen
mEGFP -pAmT-pA
GFP -pA
entiated medial SMC or neointimal cells 
d from them following Tamoxifen
intimal cells derived from other cell types 
wing Tamoxifen or all cells in corn oil mice
Cre mERmER
e mTmG reporter mice (Jackson strain: B6.129 (Cg)-Gt(ROSA)
integrated into the ROSA 26 locus. The transgene cassette is
f a floxed membrane localized Tomato tandem dimer. Following
CAG promoter now drives expression of membrane localized EGFP.
oxifen regulated cre recombinase directed to smooth muscle cells
ous transgenic mice were used for all experiments.
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5 minutes them blocked in 5% goat serum diluted in TBS
at room temperature for 1 hour. Blocked sections were
incubated for 4-5 hours at 37° with primary antibodies
to, the SM2 isoform of smooth muscle myosin heavy
chain (1:500) [11], CD31 (1:100, clone 390, Affymetrix,
eBioscience), CD68 (1:200, clone FA-11, AbD Serotec)
diluted in 5% goat serum/TBS. Some sections were in-
cubated without primary antibody as a negative control.
Following washing in TBS primary antibodies were de-
tected by incubation with anti-rabbit or anti-rat Alexa Fluor
647 (1:10,000, Jackson ImmunoResearch). After washing
slides were mounted in Prolong Gold containing DAPI
(Invitrogen) and visualized by confocal microscopy.
Quantitation of mEGFP and mTomato positive cells in
lesions
In order to count the number of mEGFP and mTomato
positive cells within the neointima of each vessel, a Z-stack
series of 1 μm optical sections were obtained from each
vessel. mEGFP and mTomato positive cells were counted
in each of the optical sections through the entire Z-stack
of images, each DAPI positive nuclei was scored as beingFigure 2 Tissue specificity of Myh11 cre ER(T2) activity. 5-week old My
once a day for 5 days. 6 weeks later tissues were harvested and analyzed b
signal can be seen only in smooth muscle cells of all the tissues examined
activity was detected in other cell types including skeletal muscle cells card
muscle, LM-longitudinal muscle, CM-circular muscle, MP-myenteric plexus,associated with either an mEGFP or mTomato positive
cell. For some sections it was possible to obtain 2 different
fields of Z-stack images.
Fluorescence activated cell sorting (FACS)
For FACS blood was harvested from mice immediately
prior to tissue collection. Blood collected into heparinized
tubes was diluted 10 fold into red blood cell lysis buffer
(168 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH7.3).
Cells were collected by brief centrifugation (5 min, 400×g),
washed in the same buffer and recentrifuged. Pelleted cells
were resuspended in phosphate buffered saline containing
0.5% bovine serum albumen, 0.5 mM EDTA and subjected
to FACS analysis. Red blood cell fragments were excluded
based on side scatter analysis and the remaining cells
sorted based on their red and green fluorescence. A mini-
mum of 10,000 cells were counted in each sample. For
each analysis, cells obtained from a mouse that expresses
EGFP ubiquitously (CAG-EGFP: C57BL/6-Tg(CAG-EGFP)
131Osb/LeySopJ) were used as a positive control for
EGFP-expressing cells. Cells obtained from a cre negative
mTmG mouse were used as a positive control for
mTomato expressing cells and cells obtained from ah11 creER(T2)-/+ mTmG-/+ mice were treated with tamoxifen (1 mg,IP)
y confocal microscopy as described in ‘Methods’. A strong mEGFP
including, bladder, colon, aorta, skeletal muscle and heart. No cre
iac myocytes, endothelial cells or mucosal epithelial cells. SM-smooth
MM-muscularis mucosa, EC-endothelial cells.
Figure 3 (See legend on next page.)
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Figure 3 Tissue specificity of Acta2 cre ER(T2) activity. 5-week old Acta2 creER(T2)-/+ mTmG-/+ mice were treated with tamoxifen (1 mg,IP)
once a day for 5 days. 2 weeks following the last tamoxifen injection the left carotid artery was ligated. 4 weeks later tissues were harvested and
analyzed by confocal microscopy as described in ‘Methods’. A strong mEGFP signal can be seen only in smooth muscle cells of all the tissues ex-
amined. No cre activity was detected in other cell types including skeletal muscle cells, cardiac myocytes, endothelial cells, mucosal epithelial cells
and hepatocytes. A heterogeneous staining was observed in the uterus suggesting that cre was not active in all the uterine smooth muscle cells
during the period in which the mice were treated with tamoxifen. The patchwork mEGFP expression observed in the esophagus reflects the
mixed skeletal/smooth muscle lineage of cells within the wall of this portion of the esophagus. SM-smooth muscle, LM-longitudinal muscle,
CM-circular muscle, MP-myenteric plexus, MM-muscularis mucosa. Scale bars represent 40 μm in all panels.
Figure 4 Myh11 expression is down-regulated 7 days following injury. 5-week old male Myh11 creER(T2)-/+ mTmG-/+ mice were treated with
tamoxifen (1 mg,IP) once a day for 5 days. Two weeks following the last tamoxifen injection the left carotid artery was ligated and tissues were harvested
7 days later. 8 μm cryosections obtained from injured and contralateral control arteries were analyzed for expression of myh11 (using an anti-SM2 antibody)
(red) and mEGFP (green) and mTomato (white). Control and injured sections are shown at identical exposures. Images shown are representative of
those obtained from 3 different mice. In the lower panels the SM2 antibody was omitted and the samples otherwise processed identically to those
shown in the upper panels. All images are shown at the same magnification with the scale bar shown in the bottom left panel representing 50 μm.
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Figure 5 Previously differentiated VSMC contribute to early neointima formation. 5-week old male Myh11 creER(T2)-/+ mTmG-/+ mice were treated
with tamoxifen (1 mg,IP) once a day for 5 days. Two weeks following the last tamoxifen injection the left carotid artery was ligated and tissues were
harvested 14 days later. Expression of mTomato (red) and mEGFP (green) were visualized in sections obtained from 4 different mice. Nuclei were visualized
by staining with DAPI (blue). All images are shown at the same magnification with the scale bar shown in the top left panel representing 50 μm.
Figure 6 CD31 positive endothelial cells can be seen within early developing neointima. Sections from two of the mice shown in Figure 5
were stained with antibodies to CD31 (white). Left panels show mTomato (red)/mEGFP (green) co-stained sections and in the right panels are the
same sections visualized for mEGFP (green) and CD31(white). Nuclei were visualized by staining with DAPI (blue). All images are shown at the
same magnification with the scale bar shown in the bottom left panel representing 50 μm.
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Gates were established based on the distribution of the
control cell groups and the numbers of cells in the experi-
mental mice that fall into each group were determined.
Results
Results of a recent study suggest that neointimal cells that
form following vascular injury are derived from a stem cell
population resident within the vascular wall rather than
from previously differentiated VSMCs [6]. In that study
fate mapping experiments were performed in which differ-
entiated VSMCs were tagged using a cre-dependent EGFP
reporter strain crossed with transgenic mice expressing
cre recombinase exclusively in smooth muscle cells (B6.
Cg-Tg(Myh11-cre,-EGFP)2Mik/J) [12]. The conclusion
that previously differentiated VSMCs do not contribute
to neointima formation was thus, based largely on the
inability to detect EGFP-positive cells in the neointima
in these mice. As there are many factors that can con-
tribute to a negative result in these experiments, includ-
ing the reported silencing of the ROSA 26 promoter
that was used to drive EGFP expression in neointimal
cells [13], we reevaluated these findings using an alter-
native fate mapping strategy. We utilized a dual color
reporter transgenic mouse line (mTmG: B6.129(Cg)-Gt
(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J) in which allFigure 7 CD68 positive macrophages/monocytes cells can be seen wi
same two mice shown in Figure 6 were stained with antibodies to CD68 (w
sections and in the right panels are the same sections visualized for mEG
the neointima of vessels from the mouse shown in the upper panels bu
were visualized by staining with DAPI (blue). All images are shown at th
panel representing 50 μm.cells express a membrane localized mTomato tandem
dimer in the absence of cre recombinase activity. Fol-
lowing cre-mediated excision of the mTomato cassette,
cells express membrane localized EGFP [14] (Figure 1).
In this reporter mouse line, both mTomato and mEGFP
are driven by the same CMV/β-actin (CAG) promoter
that has been shown to be active in neointimal cells
[13]. This dual color reporter strain obviates the need to
interpret negative data, as all neointimal cells should be
either red or green depending on whether they express
mTomato of mEGFP, respectively. To specifically iden-
tify differentiated VSMCs we crossed the mTmG mice
with mice expressing a tamoxifen regulated cre recom-
binase directed by the smooth muscle-specific Myh11
[8] or Acta2 [9] promoters. The ability to temporally
control cre recombinase activity also permitted us to
distinguish previously differentiated VSMCs from newly
differentiated VSMCs. Mice were treated with tamoxifen
to activate the cre recombinase 2 weeks prior to vascular
injury. As tamoxifen is rapidly metabolized in mice, at the
time of surgical injury and subsequently, any cre recom-
binase expressed in VSMCs will be inactive and thus un-
able to switch cells from mTomato positive to mEGFP
positive. Thus only VSMCs that were differentiated during
the period of tamoxifen treatment, prior to injury will be
mEGFP positive. As cre-mediated recombination resultsthin early developing neointima in some mice. Sections from the
hite). Left panels show mTomato (red)/mEGFP (green) co-stained
FP (green) and CD68(white). CD68-positive cells can be seen within
t not in the vessels of the mouse shown in the lower panels. Nuclei
e same magnification with the scale bar shown in the bottom left
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cells and any of their progeny will remain mEGFP positive
even if they dedifferentiate and loose expression of cre or
Myh11 or Acta2.
In Myh11 creER(T2)-/+ mTmG-/+ double transgenic
mice [8] and Acta2 creER(T2)-/+ mTmG-/+ [9] double
transgenic mice (Figure 1) treatment with tamoxifen re-
sults in cre mediated recombination and thus subse-
quent expression of mEGFP specifically in vascular and
visceral smooth muscle cells (Figures 2 and 3). No mEGFPFigure 8 Myh11-tagged medial SMCs give rise to the mature neointim
following carotid ligation of 5-week old male Myh11 creER(T2)-/+ mTmG-/+
(CO) as indicated. In the upper two panels the control and injured carotid
adventitia (adv) are indicated. Images are representative of those obtained
indicated). Arrows point to examples of endothelial cell nuclei. The image
corn oil control treated mouse. The arrow-head in this image points to an
the same magnification with the scale bars representing 50 μm.expression was observed in endothelial cells, adventitial
cells, cardiac or skeletal muscle cells (Figures 2 and 3).
7 days following injury in Myh11 creER(T2)-/+ mTmG-/+
double transgenic mice we observed a significant decrease
in expression of the endogenous Myh11 gene within the
medial layer of carotid arteries as evidenced by decreased
smooth muscle myosin isoform, SM2, immunostaining
(Figure 4). This is consistent with the previously reported
dedifferentiation of medial VSMCs that follows vascular
injury [15]. Despite the observed decreased Myh11a following carotid ligation. Tissues were harvested 28 days
mice that were previously Treated with Tamoxifen (TAM) or corn oil
arteries from the same mouse are shown. The neointima, media and
from 7 tamoxifen treated mice (Mice numbers 1,7,2,3 in Table 1, as
in the lower right hand panel is of an injured vessel obtained from a
mEGFP positive cell within the medial layer. All images are shown at
Table 1 Quantitation of mEGFP positive neointimal cells
28 days following ligation
Myh11 cre % mEGFP + Averaged from:
Mouse #
1 76 ± 9 1827 cells (18 stacks, 10 sections)
2 86 ± 4 600 cells (5 stacks, 3 sections)
3 80 ± 11 773 cells (12 stacks, 8 sections)
4 90 ± 5 653 cells (6 stacks, 4 sections)
5 92 ± 4 227 cells (5 stacks, 3 sections)
6 42 ± 10 517 cells (5 stacks, 3 sections)
7 85 ± 7 463 cells (10 stacks, 8 sections)
Mean 79 ± 17 5060 cells (61 stacks, 39 sections)
Acta2 cre % mEGFP+ Averaged from:
Mouse#
8 91 ± 4 731 cells (5 stacks, 3 sections)
9 72 ± 13 208 cells (8 stacks, 6 sections)
10 63 ± 16 189 cells (10 stacks, 6 sections)
11 74 ± 4 261 cells (6 stacks, 3 sections)
12 81 ± 7 561 cells (5 stacks, 4 sections)
13 94 ± 7 759 cells (8 stacks, 8 sections)
14 92 ± 3 190 cells (4 stacks, 4 sections)
Mean 81 ± 12 2899 cells (46 stacks, 34 sections)
In order to count the number of mEGFP and mTomato positive cells within
the neointima of each vessel (the cells between the internal elastic lamina and
the endothelial lining of the lumen), a Z-stack series of 1 μm optical sections
(XY-210 μm × 210 μm) were obtained from each vessel. mEGFP and mTomato
positive cells were counted in each of the optical sections through the entire
Z-stack of images, each DAPI positive nuclei was scored as being associated
with either an mEGFP or mTomato positive cell. The number of total cells
counted, together with the number of separate Z-stacks and sections counted
are indicated. From some sections we were able to obtain 2 separate fields of
Z-stack images, in others a single field encompassed the entire neointima.
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in control and injured vessels 7 days following injury,
suggesting that the CAG promoter, which drives
mEGFP expression, is not affected by injury (Figure 4).
At this time point we did not observe any significant
neointima formation in any of the three mice exam-
ined. In contrast, 14 days following ligation we ob-
served small amounts of neointima formation in 3 out
of 4 mice examined (Figure 5). In these mice, mEGFP
positive cells can be readily seen within the neointima
suggesting that these cells are derived from previously
differentiated (Myh11 positive) medial VSMCs. Immuno-
staining with antibodies to CD31 demonstrate that there
are also a number of CD31 positive, mTomato positive
endothelial like cells within the neointima (Figure 6).
We also observed some CD68 positive macrophage/
monocytes in the neointima of some mice although
these appeared less abundant than the CD31 positive
cells (Figure 7).
To better quantitate the contribution of mEGFP positive
cells to neointima formation we examined more mature
lesions that formed 28 days following ligation. In most
Myh11 creER(T2)-/+ mTmG-/+ double transgenic mice
28 days following carotid ligation the majority of neo-
intimal cells also expressed mEGFP (Figure 8, Table 1).
However, in one mouse the neointima was comprised
of only 42% of mEGFP positive cells (Mouse#6 in Table 1,
Figure 9B, C). In this mouse the lesion was very unusual
in that it extended out in a bulb like structure from one
side of the vessel wall (Figure 9B). Many of the mTomato
positive cells in this lesion also stained positive for either
CD31 or CD68 suggesting a large number of endothe-
lial cells and macrophages or monocytes in the lesion
(Figure 9B, C). In contrast, no CD68 positive cells were
detected in most mature lesions and only a few scat-
tered endothelial cells were seen within these lesions,
although they could be readily seen lining the residual
vessel lumens (Figure 9A). In another mouse, not
shown in Table 1, we did not observe any concentric
neointima formation 28 days following injury. In con-
trast, in this mouse there was an mEGFP negative clus-
ter of CD31 positive cells that covered approximately
50% of the vessel lumen. As this structure occurred
close to the point of ligation (<100 μm away), was very
focal only extending for about 300 μm, was atypical in
shape and comprised of CD31 positive cells we specu-
late that it was an organized thrombus rather than a
true neointimal lesion. This mouse was thus excluded
from our analyses. In control mice, given corn oil in-
stead of tamoxifen, almost all cells remained mTomato
positive and mEGFP negative (Figure 8, lower right
panel). One mEGFP positive cell can be seen in the
media of the corn oil treated vessel (green/yellow cell
indicated by arrow head). This cell likely representsone in which the creER(T2) protein has moved to the
nucleus in the absence of the tamoxifen ligand. As this
cell also seems to express some mTomato (accounting
for its yellow color) it is likely that the recombination
event occurred within a few days of tissue harvesting
such that the residual mTomato protein has not had
time to completely turn over and disappear from the
cell.
Consistent with data obtained from the Myh11 cre mice,
when previously differentiated VSMCs were tagged with
the use of Acta2 cre the majority of the neointimal cells
were mEGFP positive (range 63-94%; mean of 81 ± 12%;
Figure 10, Table 1). Although the data presented suggest
that many neointimal cells are derived from previously dif-
ferentiated (Myh11 or Acta2 positive) medial VSMCs it is
possible that these cells may be mobilized from distant
sites rather than being derived from locally resident med-
ial VSMCs. To evaluate the existence of a population of
mobile mEGFP positive cells we performed a fluorescence
activated cell sorting (FACS) analysis of blood obtained
Figure 9 CD31 and CD68 positive cells in mature neointimal lesions. Images shown are examples of mature lesions seen in 2 different
Myh11 creER(T2)-/+ mTmG-/+ mice 28 days following ligation (Mouse 4(A) and 6(B, C); Table 1). A, B. Sections were immuno-stained for the
endothelial/platelet marker CD31. Images shown are merged images showing the mTomato (red), mEGFP (green) and DAPI (blue); CD31 (white),
mEGFP (green) and DAPI (blue) or mTomato, mEGFP, CD31 and DAPI channels, as indicated. Sections obtained from the mouse shown in panel
A exhibited very few CD31 positive cells in the mature neointima; in contrast the lesion shown in panel B exhibited numerous CD31 positive,
mTomato positive, mEGFP negative cells in the neointima (examples indicated by arrow heads). C. Sections (serial to those shown in panel B)
were immuno-stained for the macrophage/monocyte marker CD68. Images shown are merged images showing the mTomato (red), mEGFP
(green) and DAPI (blue); CD68 (white), mEGFP (green) and DAPI (blue) or mTomato, mEGFP, CD68 and DAPI channels, as indicated. Several CD68
positive, mTomato positive, mEGFP negative cells can be seen in the neointima and adventitia (examples indicated by arrow heads). No CD68
positive cells were seen in the neointima of the mouse shown in panel A (data not shown).
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double transgenic mice, 7,14 and 28 days following injury
(Figure 11). This analysis failed to detect the presence of
any significant numbers of mEGFP positive circulating
cells suggesting that the mEGFP positive neointimal cells
are most likely locally derived.
Discussion
Results from the current studies support the widely ac-
cepted paradigm that following vascular injury medial
VSMCs dedifferentiate and migrate into the lumen of
vessels forming a neointima. As we utilized a tamoxifen
regulated cre recombinase and waited 2 weeks after tam-
oxifen treatment before performing carotid ligation, giventhe 12 hour half life of tamoxifen in serum, it is highly un-
likely that mEGFP positive cells seen following injury are
derived from newly differentiated cells. Moreover, the use
of a dual color reporter system avoided any artifacts that
may arise due to promoter or reporter silencing as all cells
should be either mTomato or mEGFP positive thus no
conclusions need to be drawn that are based on negative
staining data. Our data also suggest that unlike the ROSA-
LACz reporter gene [13] the CMV enhancer/chicken
beta-actin core promoter (CAG) driven mTmG reporter
gene is not down-regulated in neointimal SMCs (compare
the mEGFP intensity of control and injured vessels in
Figures 3, 8 and 10). The use of the mTmG reporter
strain has the additional advantage that the reporter
Figure 10 Acta2-tagged medial SMCs give rise to the neointima following carotid ligation. Control and injured carotid arteries from
Tamoxifen (TAM) or corn oil (CO) treated Acta2 creER(T2)-/+ mTmG-/+ transgenic mice harvested 28 days post ligation (Mice numbers 11, 12 and
13, respectively; Table 1). Images from tamoxifen treated injured vessels are representative of those obtained from 7 mice.
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during sample processing. Moreover, this is a single copy,
targeted transgene, hence, it is also not subject to compli-
cations that may arise from partial recombination of mul-
ticopy transgenes, such that in each cell’s nucleus either
the mTomato gene is present or it is excised. Cells will
thus express either mTomato or mEGFP. Anecdotally we
have noted, that the mTomato protein is relatively stable
such that after tamoxifen treatment smooth muscle cells
can have detectable expression of both mTomato and
mEGFP for 3-4 days before the mTomato protein is
turned over and degraded. We speculate that one or more
of these advantages of the mTmG reporter system andtamoxifen regulated cre transgenes used in our study may
explain why we were able to detect mEGFP positive neo-
intimal cells whereas they were not detected in a previous
study [6].
Our data are consistent with and extend previous fate
mapping studies using a cre-dependent LacZ reporter
[5]. In this study a cre-dependent ROSA-LacZ reporter
was used together with Myh11-creER(T2) transgenic
mice to show that following femoral artery wire injury
the neointima that formed contained LacZ positive cells
[5]. Together these studies suggest that in both the small
concentric lesions that form following femoral wire injury
and the more complex large lesions that form following
Figure 11 No mEGFP positive circulating cells can be detected following carotid ligation. Blood was harvested from Myh11 creER(T2)-/+
mTmG-/+ mice 7, 14 and 28 days following carotid ligation and subjected to fluorescence activated cell sorting. Cells harvested from a CAG-EGFP
mouse were used as positive controls for EGFP expressing cells, those harvested from mTmG reporter mice with no cre transgene as positive
controls for mTomato positive cells and those harvested from nontransgenic mice as negative controls. From each mouse a minimum of 10,000
cells were sorted. Upper panels show the distribution of mTomato (red) and mEGFP (green) positive as well as negative (black) cells. Numbers on
each graph show the percentage of negative cells in each quadrant. Lower panels show the distribution of cells obtained from duplicate Myh11
creER(T2)-/+ mTmG-/+ mice. In each case the percentage of EGFP-positive cells are less than background negative control levels.
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medial VSMCs. Our rigorous quantitative analysis using
1 μm optical sections to obtain Z-stack series through the
entire thickness of each 8 μm section, revealed some
heterogeneity between mice, with mEGFP positive cellscomprising 42-94% of total neointimal cells (Table 1).
Although most mice have between 70-90% mEGFP posi-
tive neointimal cells, this may perhaps account for some
of confusion in the literature related to the contribution of
different cell types to the neointima. Despite this variability,
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http://www.vascularcell.com/content/6/1/21the data indicate that, on average, the majority (~80%) of
neointimal cells arise from the previously differentiated
medial SMCs. This number would be consistent with pre-
vious studies that showed that about 20% of neointimal
cells are derived from blood borne cells [4]. In further
support of the contribution of blood or endothelial de-
rived cells to the neointima some of the mTomato posi-
tive, mEGFP negative neointimal cells observed in our
study, stained positive for endothelial and monocyte
markers (CD31 and CD68, respectively; Figures 6, 7 and 9).
It is perhaps a little surprising that in some lesions there
were more CD31 positive endothelial cells within the le-
sions than CD68 positive monocytes/macrophages.
Some of these CD31 positive endothelial cells may be
present in new vessels that are growing within the neo-
intima (e.g. Figure 6, lower panels) and some may be
miscounted lumen endothelial cells in which the plane
of the section has obscured a luminal invagination. We
also speculate that the proliferating neointimal smooth
muscle cells may trap endothelial cells within the lesion
as they extend out into the vessel lumen.
Conclusions
Although our studies do not rule out the possibility that
under appropriate, in vitro, culture conditions the ex-
pansion of a progenitor cell population may be favored,
the current studies provide compelling evidence that,
in vivo, the majority of neointimal cells that arise following
carotid ligation are derived from differentiated medial
VSMCs. The lack of detectable mEGFP positive cells cir-
culating in the blood, further suggests that the neointimal
cells likely arise from the dedifferentiation and migration
of locally derived medial VSMCs.
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